---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-035785"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T04:49:00.525009+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protara reports 100% CR at any time in BCG-unresponsive NMIBC; 67% at 12 months

## Summary
- BCG-Unresponsive: 100% CR at any time (5/5), 67% at 12 months (2/3) as of April 16, 2025 cutoff.
- BCG-Naïve: 76% CR at any time (16/21), 43% at 12 months (3/7) in Phase 2 ADVANCED-2 trial.
- No Grade 3+ treatment-related adverse events; most AEs were Grade 1, transient, and consistent with immunopotentiation.
- Company on track to present interim data from ~25 six-month evaluable BCG-Unresponsive patients by end of 2025.

## SEC filing metadata
- accession: 0001213900-25-035785
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025035785/0001213900-25-035785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025035785/ea0239689-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-035785
- JSON: https://secwatch.observer/filing/0001213900-25-035785.json
- Plain text: https://secwatch.observer/filing/0001213900-25-035785.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.